Brief: Vaccitech Reports Promising Interim Efficacy Analysis In Phase 1B/2A Clinical Study In Chronic HBV

Barinthus Biotherapeutics

07/12/2021 13:17

Dec 7 (Reuters) - Vaccitech PLC  VACC.O :
    * VACCITECH REPORTS PROMISING INTERIM EFFICACY ANALYSIS IN
PHASE
1B/2A CLINICAL STUDY IN CHRONIC HBV
    * VACCITECH PLC -  INTERIM DATA FROM 27 PATIENTS
DEMONSTRATED
NOTED CHANGES IN SURFACE ANTIGEN (HBSAG) LEVELS
    * VACCITECH PLC - ENROLLMENT INTO HBV002 WILL CONTINUE INTO
2022
    * VACCITECH PLC - FURTHER INTERIM ANALYSIS, INCLUDING MORE
HBSAG
LEVEL DATA, IS ANTICIPATED DURING FIRST HALF OF 2022

Source text for Eikon:  ID:nGNX8K1Xxv 
Further company coverage:  VACC.O 

 ((Reuters.Briefs@thomsonreuters.com;))